Cargando…
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
PURPOSE OF REVIEW: The treatment strategy for BRAF-mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has improved the prognosis of advanced melanoma. This article reports current evidence on the efficacy and safety of sequential immunotherapy with targeted...
Autores principales: | Trojaniello, Claudia, Sparano, Francesca, Cioli, Eleonora, Ascierto, Paolo Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164000/ https://www.ncbi.nlm.nih.gov/pubmed/36995534 http://dx.doi.org/10.1007/s11912-023-01402-8 |
Ejemplares similares
-
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
por: Ascierto, Paolo A., et al.
Publicado: (2023) -
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
por: Trojaniello, Claudia, et al.
Publicado: (2021) -
The immune‐related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2014) -
The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015) -
Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)